FDA Accepts Celcuity's REVTORPYK Application; Decision Expected In June 2027; Stock Up
Celcuity Inc. (CELC) announced the FDA accepted its sNDA for REVTORPYK (gedatolisib) to treat HR+/HER2-negative, PIK3CA-mutated advanced breast cancer. A decision is expected by June 25, 2027. The drug targets the PI3K/AKT/mTOR pathway and is supported by Phase 3 trial data. CELC stock rose 5.17% to $70.24.
How this was made
The 30-second read
Why it matters
Regulatory acceptance reduces development risk, supporting a near‑term price rally while longer‑term upside depends on eventual approval.
Market read
The news provides a fresh regulatory milestone for a small‑cap biotech, likely prompting short‑term buying pressure.
What to watch
Potential competition from other PI3K inhibitors and the need for robust Phase 3 data could limit upside.
Background
Celcuity is a commercial‑stage biotech developing gedatolisib, a pan‑PI3K/mTOR inhibitor, for HR+/HER2‑negative breast cancer.
Ticker impact
FDA accepted Celcuity's supplemental NDA for REVTORPYK, setting a PDUFA decision date in June 2027.
likely upward pressure as the market prices in the regulatory acceptance and potential future approval.
Regulatory acceptance of a sNDA is a material event for a biotech; the stock already rose 5% on the news, indicating immediate buying interest.
Market effects
Strengthens the oncology/PI3K‑targeted therapy segment, potentially boosting peer biotech valuations.
Limited to U.S. biotech market; no broader regional effect.
Modest global relevance, mainly for investors tracking FDA pipeline progress.
Counterpoint
The long PDUFA timeline (2027) may dilute the short‑term catalyst, and the market could have already priced in the acceptance.
Key entities
- companyCelcuity Inc.
Biotech developing REVTORPYK (gedatolisib).
- regulatorFDA
U.S. Food and Drug Administration reviewing the sNDA.
